Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
CV Sciences, Inc. is a U.S.-based consumer health and wellness company operating primarily in the hemp-derived cannabidiol (CBD) industry. The company focuses on the development, manufacturing, and marketing of CBD-based products that are positioned for consumer wellness and nutraceutical markets. Its activities place it at the intersection of the dietary supplements, natural health products, and consumer packaged goods industries.
The company’s primary revenue driver is its consumer CBD product portfolio, marketed under the PlusCBD brand, which includes oils, gummies, capsules, topicals, and sprays. CV Sciences differentiates itself through an emphasis on quality control, compliance with evolving regulatory standards, and clinical research supporting CBD efficacy. The company was founded in 2010 and initially focused on biotechnology before pivoting into hemp-derived CBD following changes in U.S. hemp legislation, notably after the 2014 and 2018 Farm Bills enabled broader commercialization of hemp-based products.
Business Operations
CV Sciences generates revenue through the formulation, manufacturing, and distribution of hemp-derived CBD consumer products. Its core operating segment is its Consumer Products business, which encompasses branded CBD wellness offerings sold through natural product retailers, specialty stores, e-commerce platforms, and select mass-market channels. The company also previously operated a drug development segment focused on cannabinoid-based therapeutics, though this area has been significantly reduced to prioritize near-term revenue and cost efficiency.
Operations are primarily domestic within the United States, with manufacturing and supply chain activities supported by third-party partners. CV Sciences operates through its wholly owned subsidiary Plus Products LLC, which manages brand marketing, product development, and distribution. The company maintains relationships with independent growers, extractors, and contract manufacturers to support scalability while limiting capital-intensive asset ownership.
Strategic Position & Investments
CV Sciences’ strategic direction centers on stabilizing revenue, strengthening liquidity, and reinforcing its position in the highly competitive CBD wellness market. Key initiatives include streamlining product offerings, focusing on higher-margin SKUs, and expanding distribution in regulated retail channels such as natural grocery chains and practitioner-based networks. The company emphasizes compliance, product testing, and transparency as a means of differentiation in a fragmented market.
Historically, CV Sciences invested in cannabinoid drug development and intellectual property related to CBD formulations, including clinical research supporting its products. While it has not announced major acquisitions in recent years, the company continues to treat its PlusCBD brand as its core strategic asset. Its exposure to emerging health and wellness trends remains tied to consumer adoption of hemp-derived supplements rather than speculative cannabis or THC-focused markets.
Geographic Footprint
CV Sciences is headquartered in San Diego, California, and its operational footprint is primarily concentrated in North America. The majority of its revenue is derived from sales within the United States, where its products are distributed across all 50 states in compliance with federal hemp regulations.
International exposure has been limited and opportunistic rather than a primary growth driver. While the PlusCBD brand has had some international distribution historically, particularly in parts of Europe, the company’s strategic focus remains on strengthening its domestic presence amid ongoing regulatory uncertainty in global CBD markets.
Leadership & Governance
CV Sciences is led by an executive team with experience in consumer packaged goods, finance, and regulated wellness industries. Leadership has emphasized disciplined capital management, regulatory compliance, and rebuilding investor confidence following periods of financial strain in the CBD sector.
Key executives include:
- Joseph Dowling – Chief Executive Officer
- Paul Ried – Chief Financial Officer
- Brian McAndrew – Vice President of Sales
- Joseph Yanchik – General Counsel and Corporate Secretary
The company operates under a publicly traded governance structure and is subject to U.S. securities reporting requirements. Leadership has articulated a strategic vision focused on operational efficiency, brand credibility, and long-term participation in the mainstream health and wellness market.